{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:55:20Z","timestamp":1787028920390,"version":"build-2736575974"},"reference-count":39,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Hyperleukocytosis in acute myeloid leukemia (AML) is life-threatening, often complicated by leukostasis, tumor lysis syndrome (TLS), and disseminated intravascular coagulation (DIC), with very high early mortality. Leukapheresis (LA) can rapidly reduce circulating blast burden, but its effect on survival and prognostic relevance of disease markers remains unclear. Materials and Methods: We retrospectively analyzed 74 adult AML patients with WBC &gt; 100 \u00d7 109\/L treated at the University Clinical Center of Serbia between 2014 and 2024: 28 received LA plus cytoreduction (LA group), and 46 received cytoreduction alone (non-LA group). We evaluated 15-, 30-, and 90-day mortality and overall survival (OS), and assessed clinical, laboratory, and immunophenotypic predictors using Cox regression, with separate subgroup analyses. Results: Patients in the LA group had significantly higher baseline leukocyte counts and LDH (p = 0.18 and p = 0.024, respectively). Although LA resulted in a median 34% reduction in WBC, there was no statistically significant difference in early mortality: 15-day survival was 68% vs. 76% (HR 0.70, p = 0.423), 30-day survival 50% vs. 65% (HR 0.62, p = 0.197), and 90-day survival 39.3% vs. 41.3% (HR 0.85, p = 0.604). Median OS was similarly poor, about 1 month in the LA group compared to 2 months in the non-LA (HR 0.73). Across all patients, ECOG PS \u22652, elevated LDH, TLS, and DIC were the strongest indicators of early death. In the LA group, elevated LDH and increased peripheral blood (PB) monocyte count predicted 15-day mortality (p = 0.021 and p = 0.031, respectively), but lost significance by day 90. In non-LA patients, CD25 positivity (p = 0.034) and DIC (p = 0.045) predicted 15-day death. By day 90, CD25 expression (p = 0.048) remained prognostic, while PB blast percentage (p = 0.045) and PB monocyte count (p = 0.017) emerged as additional adverse prognostic predictors in the non-LA group. In multivariate analysis, higher PB blast percentage, CD25 positivity, and ECOG PS \u2265 2 independently predicted poorer OS. Conclusions: Although LA did not reduce early mortality in the entire cohort, the loss of prognostic significance of elevated LDH, high PB blast percentage, PB monocyte burden, and CD25 expression in the LA group may suggest that the intervention can attenuate the impact of biologically aggressive disease.<\/jats:p>","DOI":"10.3390\/medicina62010035","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T14:27:51Z","timestamp":1766586471000},"page":"35","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of Leukapheresis and Biological Risk Markers on Early Mortality in Patients with Hyperleukocytic Acute Myeloid Leukemia"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0907-7552","authenticated-orcid":false,"given":"Mirjana","family":"\u010cu\u010dakovi\u0107","sequence":"first","affiliation":[{"name":"Clinic of Hematology, University Clinical Centre of Serbia, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7130-1912","authenticated-orcid":false,"given":"Lazar","family":"Trajkovi\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, University Clinical Centre of Serbia, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"Dini\u0107","sequence":"additional","affiliation":[{"name":"Department for Therapeutic Apheresis Procedures and Intraoperative Blood Salvage, University Clinical Center of Serbia, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7798-4026","authenticated-orcid":false,"given":"Nikola","family":"Panti\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, University Clinical Centre of Serbia, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5488-126X","authenticated-orcid":false,"given":"Nikica","family":"Sablji\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, University Clinical Centre of Serbia, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5095-7327","authenticated-orcid":false,"given":"Zlatko","family":"Pravdi\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, University Clinical Centre of Serbia, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jovan","family":"Raji\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, University Clinical Centre of Serbia, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violeta","family":"Milo\u0161evi\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, University Clinical Centre of Serbia, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8313-3754","authenticated-orcid":false,"given":"Mirjana","family":"Mitrovi\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, University Clinical Centre of Serbia, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Vidovi\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, University Clinical Centre of Serbia, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8807-4797","authenticated-orcid":false,"given":"Nada","family":"Suvajd\u017ei\u0107-Vukovi\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, University Clinical Centre of Serbia, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8288-7308","authenticated-orcid":false,"given":"Andrija","family":"Bogdanovi\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, University Clinical Centre of Serbia, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2400-0112","authenticated-orcid":false,"given":"Ljubomir","family":"Jakovi\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, University Clinical Centre of Serbia, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4626-4215","authenticated-orcid":false,"given":"Marijana","family":"Virijevi\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, University Clinical Centre of Serbia, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute Myeloid Leukemia","volume":"373","author":"Weisdorf","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/ajh.27625","article-title":"Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-stratification, and Management","volume":"100","author":"Shimony","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Pastore, F., Pastore, A., Wittmann, G., Hiddemann, W., and Spiekermann, K. (2014). The Role of Therapeutic Leukapheresis in Hyperleukocytotic AML. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0095062"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.blre.2012.01.003","article-title":"Hyperleukocytosis, Leukostasis and Leukapheresis: Practice Management","volume":"26","author":"Ganzel","year":"2012","journal-title":"Blood Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/16078454.2021.2024939","article-title":"Comparison of Early Mortality between Leukapheresis and Non-Leukapheresis in Adult Acute Myeloid Leukemia Patients with Hyperleukocytosis: A Systematic Review and Meta-Analysis","volume":"27","author":"Rinaldi","year":"2022","journal-title":"Hematology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1182\/blood-2014-10-551507","article-title":"How I Treat Hyperleukocytosis in Acute Myeloid Leukemia","volume":"125","author":"Ehninger","year":"2015","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and Management of AML in Adults: 2022 Recommendations from an International Expert Panel on Behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Bewersdorf, J.P., and Zeidan, A.M. (2020). Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments?. Cells, 9.","DOI":"10.3390\/cells9102310"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/17474086.2020.1751609","article-title":"Leukocytapheresis for Patients with Acute Myeloid Leukemia Presenting with Hyperleukocytosis and Leukostasis: A Contemporary Appraisal of Outcomes and Benefits","volume":"13","author":"Shallis","year":"2020","journal-title":"Expert Rev. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1182\/blood.V60.2.279.279","article-title":"Hyperleukocytic Leukemias: Rheological, Clinical, and Therapeutic Considerations","volume":"60","author":"Lichtman","year":"1982","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.transci.2018.02.006","article-title":"The Management of Hyperleukocytosis in 2017: Do We Still Need Leukapheresis?","volume":"57","author":"Korkmaz","year":"2018","journal-title":"Transfus. Apher. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10428190009053534","article-title":"Hyperleukocytic Leukemias and Leukostasis: A Review of Pathophysiology, Clinical Presentation and Management","volume":"39","author":"Porcu","year":"2000","journal-title":"Leuk. Lymphoma"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1182\/blood.V97.7.2121","article-title":"Endothelial Cell Activation by Myeloblasts: Molecular Mechanisms of Leukostasis and Leukemic Cell Dissemination","volume":"97","author":"Stucki","year":"2001","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000341805","article-title":"Leukocyte Depletion by Therapeutic Leukocytapheresis in Patients with Leukemia","volume":"39","author":"Moog","year":"2012","journal-title":"Transfus. Med. Hemother."},{"key":"ref_15","first-page":"1037","article-title":"Leukapheresis Induced Changes in Cell Cycle Distribution and Nucleoside Transporters in Patients with Untreated Acute Myeloid Leukemia","volume":"5","author":"Powell","year":"1991","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/jca.21705","article-title":"Guidelines on the Use of Therapeutic Apheresis in Clinical Practice\u2014Evidence-based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue","volume":"34","author":"Padmanabhan","year":"2019","journal-title":"J. Clin. Apher."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1111\/j.1537-2995.2007.01406.x","article-title":"Impact of Leukapheresis on Early Death Rate in Adult Acute Myeloid Leukemia Presenting with Hyperleukocytosis","volume":"47","author":"Bug","year":"2007","journal-title":"Transfusion"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1080\/10428194.2016.1277386","article-title":"Leukapheresis Reduces 4-Week Mortality in Acute Myeloid Leukemia Patients with Hyperleukocytosis\u2014A Retrospective Study from a Tertiary Center","volume":"58","author":"Nan","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/jca.22090","article-title":"Effectiveness of Leukapheresis on Early Survival in Acute Myeloid Leukemia: An Observational Propensity Score Matching Cohort Study","volume":"38","author":"Lee","year":"2023","journal-title":"J. Clin. Apher."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1038\/s41375-020-0783-3","article-title":"Management of Hyperleukocytosis and Impact of Leukapheresis among Patients with Acute Myeloid Leukemia (AML) on Short- and Long-Term Clinical Outcomes: A Large, Retrospective, Multicenter, International Study","volume":"34","author":"Stahl","year":"2020","journal-title":"Leukemia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2147\/JBM.S312140","article-title":"Leukapheresis Does Not Improve Early Survival Outcome of Acute Myeloid Leukemia with Leukostasis Patients\u2014A Dual-Center Retrospective Cohort Study","volume":"12","author":"Rinaldi","year":"2021","journal-title":"J. Blood Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/trf.14329","article-title":"The Effect of Therapeutic Leukapheresis on Early Complications and Outcomes in Patients with Acute Leukemia and Hyperleukocytosis: A Propensity Score-matched Study","volume":"58","author":"Choi","year":"2018","journal-title":"Transfusion"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/bjh.13146","article-title":"A Retrospective Observational Study of Leucoreductive Strategies to Manage Patients with Acute Myeloid Leukaemia Presenting with Hyperleucocytosis","volume":"168","author":"Kuo","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1182\/blood.V122.21.5046.5046","article-title":"Treatment with Leukapheresis in Patients Diagnosed with Hyperleukocytic Acute Myeloid Leukemia","volume":"122","author":"Montesinos","year":"2013","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 Revision to the World Health Organization Classification of Myeloid Neoplasms and Acute Leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and Management of AML in Adults: 2017 ELN Recommendations from an International Expert Panel","volume":"129","author":"Estey","year":"2017","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and Response Criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1001\/jamaoncol.2017.2714","article-title":"Development and Validation of a Novel Acute Myeloid Leukemia\u2013Composite Model to Estimate Risks of Mortality","volume":"3","author":"Sorror","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/jth.14134","article-title":"Subcommittee on Disseminated Intravascular Coagulation. A Re-Evaluation of the D-Dimer Cut-off Value for Making a Diagnosis According to the ISTH Overt-DIC Diagnostic Criteria: Communication from the SSC of the ISTH","volume":"16","author":"Suzuki","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1365-2141.2010.08143.x","article-title":"TLS Expert Panel. Recommendations for the Evaluation of Risk and Prophylaxis of Tumour Lysis Syndrome (TLS) in Adults and Children with Malignant Diseases: An Expert TLS Panel Consensus","volume":"149","author":"Cairo","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_31","first-page":"332","article-title":"Acute Kidney Injury in Patients with Severe Sepsis or Septic Shock: A Comparison between the \u201cRisk, Injury, Failure, Loss of Kidney Function, End-Stage Kidney Disease\u201d (RIFLE), Acute Kidney Injury Network (AKIN) and Kidney Disease: Improving Global Outcomes (KDIGO) Classifications","volume":"10","author":"Pereira","year":"2017","journal-title":"Clin. Kidney J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1002\/cncr.34495","article-title":"Molecular Profiling of Patients with Cytogenetically Normal Acute Myeloid Leukemia and Hyperleukocytosis","volume":"128","author":"Pastore","year":"2022","journal-title":"Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/17474086.2021.1886920","article-title":"The Important Role of Intensive Induction Chemotherapy in the Treatment of Acute Myeloid Leukemia","volume":"14","author":"Lin","year":"2021","journal-title":"Expert Rev. Hematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1080\/10428194.2020.1728753","article-title":"Patterns of Care and Clinical Outcomes of Patients with Newly Diagnosed Acute Myeloid Leukemia Presenting with Hyperleukocytosis Who Do Not Receive Intensive Chemotherapy","volume":"61","author":"Shallis","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1526-0968.2002.00402.x","article-title":"Leukocytoreduction for Acute Leukemia","volume":"6","author":"Porcu","year":"2002","journal-title":"Ther. Apher."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.2147\/IJGM.S321787","article-title":"Leukapheresis and Hyperleukocytosis, Past and Future","volume":"14","author":"Zhang","year":"2021","journal-title":"Int. J. Gen. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1182\/blood-2012-02-414425","article-title":"CD25 Expression Status Improves Prognostic Risk Classification in AML Independent of Established Biomarkers: ECOG Phase 3 Trial, E1900","volume":"120","author":"Sun","year":"2012","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Li, J., Ran, Q., Xu, B., Luo, X., Song, S., Xu, D., and Zhang, X. (2020). Role of CD25 Expression on Prognosis of Acute Myeloid Leukemia: A Literature Review and Meta-Analysis. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0236124"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Farid, K.M.N., Sauer, T., Schmitt, M., M\u00fcller-Tidow, C., and Schmitt, A. (2023). Symptomatic Patients with Hyperleukocytic FLT3-ITD Mutated Acute Myeloid Leukemia Might Benefit from Leukapheresis. Cancers, 16.","DOI":"10.3390\/cancers16010058"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/1\/35\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T14:52:52Z","timestamp":1766587972000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/1\/35"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["medicina62010035"],"URL":"https:\/\/doi.org\/10.3390\/medicina62010035","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]}}}